DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including PD-1 Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the PD-1 Non-Small Cell Lung Cancer pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, PD-1 Non-Small Cell Lung Cancer clinical trials studies, PD-1 Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, PD-1 Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

 

• Over 30+ PD-1 Non-Small Cell Lung cancer companies are evaluating 30+ PD-1 Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the PD-1 Non-Small Cell Lung Cancer market would significantly increase market revenue.

 

• The leading PD-1 Non-Small Cell Lung Cancer Companies include Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Bristol Myers Squibb, Sanofi, IO Biotech, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, and others.

 

• Promising PD-1 Non-Small Cell Lung Cancer Pipeline Therapies includes REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, DV281, Breath Actuated Nebulizer, DV281 (RP2D), AK105, carboplatin, pemetrexed, Tislelizumab, Docetaxel, TSR-042 (Dostarlimab), MK-3475, and others.

 

• The PD-1 Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Non-Small Cell Lung Cancer R&D. The PD-1 Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve PD-1 Non-Small Cell Lung Cancer.

 

 

To explore more information on the latest breakthroughs in the PD-1 Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook

 

PD-1 Non-Small Cell Lung Cancer Overview

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.

 

Latest Developmental Activities or News of PD-1 Non-Small Cell Lung Cancer Treatment Landscape

 

• In February 2021, Arcus Biosciences initiated a Randomized Phase III Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined withAB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

 

• Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term.

 

For further information, refer to the detailed PD-1 Non-Small Cell Lung Cancer Unmet Needs, PD-1 Non-Small Cell Lung Cancer Market Drivers, and PD-1 Non-Small Cell Lung Cancer Market Barriers, click here for PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile

 

• REGN2810 (cemiplimab) plus Ipilimumab Combination Therapy (REGN2810/ipi): Regeneron Pharmaceuticals / Sanofi

REGN2810 (SAR439684) is an antibody-based cancer therapy that Regeneron Pharmaceuticals is developing in collaboration with Sanofi. REGN2810 is a monoclonal antibody, or manmade copy of a protein that immune cells generate to fight invaders. It targets a protein called programmed cell death 1, or PD-1, on the surface of immune T-cells and precursor B-cells, or pro-B cells. Precursor B-cells are immature white blood cells that develop into fully formed B-cells. PD-1 suppresses the immune system by binding to programmed death-ligand 1, or PD-L1 — another cell surface protein that several cancers overproduce. By binding with PD-1, REGN 2810 blocks the interaction between PD-1 and PD-L1, promoting T-cell growth and survival. The result is a revved-up immune system that can then attack cancer cells.

Regeneron Pharmaceuticals is conducting a randomized, phase 3, open-label study of combinations of REGN2810 (Anti-PD-1 Antibody), platinum-based doublet chemotherapy, and ipilimumab (Anti-CTLA-4 Antibody) versus pembrolizumab monotherapy in first-line treatment of patients with advanced or metastatic Non-Small Cell Lung Cancer with tumors expressing PD-L1 ≥50%.

 

• Tislelizumab (BGB-A317) – BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

 

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for PD-1 Non-Small Cell Lung Cancer. The companies which have their PD-1 Non-Small Cell Lung Cancer drug candidates in the advanced stage, i.e. pre-registration and phase III include, BeiGene, Regeneron Pharmaceuticals, Sanofi etc.

 

Request a sample and discover the recent advances in PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ PD-1 Non-Small Cell Lung Cancer Treatment Landscape

 

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

 

• Coverage- Global
• PD-1 Non-Small Cell Lung CancerCompanies- Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Bristol Myers Squibb, Sanofi, IO Biotech, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, and others.
• PD-1 Non-Small Cell Lung Cancer Pipeline Therapies- REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, DV281, Breath Actuated Nebulizer, DV281 (RP2D), AK105, carboplatin, pemetrexed, Tislelizumab, Docetaxel, TSR-042 (Dostarlimab), MK-3475, and others.
• PD-1 Non-Small Cell Lung Cancer Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for PD-1 Non-Small Cell Lung Cancer Market Drivers and PD-1 Non-Small Cell Lung Cancer Market Barriers, click here @ PD-1 Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. PD-1 Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. PD-1 Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. PD-1 Non-Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Tislelizumab: BeiGene
11. Drug profiles in the detailed report…..
12. Late Stage Products (Phase III)
13. REGN2810/ipi: Regeneron Pharmaceuticals / Sanofi
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. RG 7769: Roche
17. Early Stage Products (Phase I)
18. TQ B2450: Apollomics; Chia Tai Tianqing Pharmaceutical Group
19. Drug profiles in the detailed report…..
20. Pre-clinical and Discovery Stage Products
21. Drug profiles in the detailed report…..
22. Inactive Products
23. PD-1 Non-Small Cell Lung Cancer Key Companies
24. PD-1 Non-Small Cell Lung Cancer Key Products
25. PD-1 Non-Small Cell Lung Cancer- Unmet Needs
26. PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers
27. PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
28. PD-1 Non-Small Cell Lung Cancer Analyst Views
29. PD-1 Non-Small Cell Lung Cancer Key Companies
30. Appendix

 

Got Queries? Find out the related information on PD-1 Non-Small Cell Lung Cancer Mergers and acquisitions, PD-1 Non-Small Cell Lung Cancer Licensing Activities @ PD-1 Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services